US 2020/0246423 Al  46  Aug. 6, 2020  TABLE I.I-continued  [0238]  In some embodiments, the formulation can include  aflibercept (e.g., at any of the final concentrations described  herein); about 0.5% w/v to about 6% w/v (e.g., about 1.0%  w/v to about 6% w/v, about 2.0% w/v to about 6% w/v, about  3.0% w/v to about 6.0% w/v, about 4.0% w/v to about 6.0%  w/v, about 5.0% w/v to about 6.0% w/v) of a sugar (e.g.,  sucrose); about 1 mM to about 60 mM (e.g., about 1 mM to  about 50 mM, about 1 mM to about 40 mM, about 1 mM to  about 30 mM, about 1 mM to about 20 mM, about 1 mM to  about 10 mM, about 5 mM to about 60 mM, about 5 mM to  about 50 mM, about 5 mM to about 40 mM, about 5 mM to  about 30 mM, about 5 mM to about 20 mM, about 5 mM to  about 10 mM, about 10 mM to about 60 mM, about 10 mM  to about 50 mM, about 10 mM to about 40 mM, about 10  mM to about 30 mM, about 10 mM to about 20 mM, about  20 mM to about 60 mM, about 20 mM to about 50 mM,  about 20 mM to about 40 mM, about 20 mM to about 30  mM, about 30 mM to about 60 mM, about 30 mM to about  50 mM, about 30 mM to about 40 mM, about 40 mM to  about 60 mM, about 40 mM to about 50 mM, or about 50  mM to about 60 mM) of a salt ( e.g., NaCl); about 0.01 % w/v  to about 0.1% w/v (e.g., about 0.01% w/v to about 0.05%  w/v) of a stabilizer (e.g., any of the stabilizers described  herein, e.g., any of the polysorbates described herein);  having a pH of about 5.5 to about 6.2 (e.g., about 6.0), and  is free of buffer.  to about 1 mM, about 0.5 mM to about 10 mM, about 0.5  mM to about 8 mM, about 0.5 mM to about 6 mM, about 0.5  mM to about 4 mM, about 0.5 mM to about 2 mM, about 0.5  mM to about 1 mM, about 1 mM to about 10 mM, about 1  mM to about 8 mM, about 1 mM to about 6 mM, about 1  mM to about 4 mM, about 1 mM to about 2 mM, about 2  mM to about 10 mM, about 2 mM to about 8 mM, about 2  mM to about 6 mM, about 2 mM to about 4 mM, about 4  mM to about 10 mM, about 4 mM to about 8 mM, about 4  mM to about 6 mM, about 6 mM to about 10 mM, about 6  mM to about 8 mM, or about 8 mM to about 10 mM) about  a buffer (e.g., any of the buffers described herein, e.g.,  histidine or imidazole buffer); about 1 mM to about 60 mM  ( e.g., about 1 mM to about 50 mM, about 1 mM to about 40  mM, about 1 mM to about 30 mM, about 1 mM to about 20  mM, about 1 mM to about 10 mM, about 5 mM to about 60  mM, about 5 mM to about 50 mM, about 5 mM to about 40  mM, about 5 mM to about 30 mM, about 5 mM to about 20  mM, about 5 mM to about 10 mM, about 10 mM to about  60 mM, about 10 mM to about 50 mM, about 10 mM to  about 40 mM, about 10 mM to about 30 mM, about 10 mM  to about 20 mM, about 20 mM to about 60 mM, about 20  mM to about 50 mM, about 20 mM to about 40 mM, about  20 mM to about 30 mM, about 30 mM to about 60 mM,  about 30 mM to about 50 mM, about 30 mM to about 40  mM, about 40 mM to about 60 mM, about 40 mM to about  50 mM, or about 50 mM to about 60 mM) of a salt (e.g.,  NaCl); about 0.01% w/v to about 0.1% w/v (e.g., about  0.01 % w/v to about 0.05% w/v) of a stabilizer ( e.g., any of  the stabilizers described herein, e.g., any of the polysorbates  described herein); having a pH of about 5.5 to about 6.2  (e.g., about 6.0).  [0239]  In some embodiments, the formulation can include  aflibercept (e.g., at any of the final concentrations described  herein); about 0.5% w/v to about 6% w/v (e.g., about 1.0%  w/v to about 6% w/v, about 2.0% w/v to about 6% w/v, about  3.0% w/v to about 6.0% w/v, about 4.0% w/v to about 6.0%  w/v, about 5.0% w/v to about 6.0% w/v) of a sugar (e.g.,  sucrose); about 0.01% w/v to about 0.1% w/v (e.g., about  0.01 % w/v to about 0.05% w/v) of a stabilizer ( e.g., any of  the stabilizers described herein, e.g., any of the polysorbates  described herein); having a pH of about 5.5 to about 6.2  ( e.g., about 6.0), and is free of buffer.  [0241]  In some embodiments, the formulation can include  aflibercept (e.g., at any of the final concentrations described  herein); about 0.5% w/v to about 6% w/v (e.g., about 1.0%  w/v to about 6% w/v, about 2.0% w/v to about 6% w/v, about  3.0% w/v to about 6.0% w/v, about 4.0% w/v to about 6.0%  w/v, about 5.0% w/v to about 6.0% w/v) of a sugar (e.g.,  sucrose); and is free of both a buffer and an organic  co-solvent.  [0242]  In some embodiments, the formulation can include  aflibercept (e.g., at any of the final concentrations described  herein); about 0.5% w/v to about 6% w/v (e.g., about 1.0%  w/v to about 6% w/v, about 2.0% w/v to about 6% w/v, about  3.0% w/v to about 6.0% w/v, about 4.0% w/v to about 6.0%  w/v, about 5.0% w/v to about 6.0% w/v) of a sugar (e.g.,  [0240]  In some embodiments, the formulation can include  aflibercept (e.g., at any of the final concentrations described  herein); about 0.5% w/v to about 6% w/v (e.g., about 1.0%  w/v to about 6% w/v, about 2.0% w/v to about 6% w/v, about  3.0% w/v to about 6.0% w/v, about 4.0% w/v to about 6.0%  w/v, about 5.0% w/v to about 6.0% w/v) of a sugar (e.g.,  sucrose); about 0.1 mMto about 10 mM (e.g., about 0.1 mM  to about 8 mM, about 0.1 mM to about 6 mM, about 0.1 mM  to about 4 mM, about 0.1 mM to about 2 mM, about 0.1 mM  Form  Buffer  Sucrose  Salt  No.  pH  (mM)  (mM)  (mM)  PS 20  1-12  5.2  0  180  0  0.03%  1-13  5.5  0  180  0  0.03%  1-14  5.8  0  180  0  0.03%  1-15  5.2  0  180  10 mM CaC1$_{2 }$ 0.03%  1-16  5.5  0  180  10 mM CaC1$_{2 }$ 0.03%  1-17  5.8  0  180  10 mM CaC1$_{2 }$ 0.03%  1-18  5.5  10 mM Histidine  180  0  0  1-19  6.0  10 mM Histidine  180  0  0  1-20  6.3  10 mM Histidine  180  0  0  1-21  5.5  10 mM Histidine  180  10 mM CaC1$_{2 }$ 0  1-22  6.0  10 mM Histidine  180  10 mM CaC1$_{2 }$ 0  1-23  6.3  10 mM Histidine  180  10 mM CaC1$_{2 }$ 0  1-24  5.2  0  180  10 mM CaC1$_{2 }$ 0  1-25  5.5  0  180  10 mM CaC1$_{2 }$ 0  1-26  5.8  0  180  10 mM CaC1$_{2 }$ 0 